Abiraterone acetate/niraparib - Janssen
Alternative Names: AKEEGA; CJNJ-67652000Latest Information Update: 17 Mar 2026
At a glance
- Originator Janssen
- Class Androstenols; Antiandrogens; Antineoplastics; Benzamides; Indazoles; Phenanthrenes; Piperidines; Pyridines; Small molecules
- Mechanism of Action CYP17A1 protein inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
Most Recent Events
- 09 Mar 2026 Registered for Prostate cancer (Combination therapy, Metastatic disease) in Norway, Iceland, Liechtenstein, European Union (PO)
- 30 Jan 2026 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopts positive opinion for Abiraterone acetate/niraparib (AKEEGA®) in Prostate cancer (Combination therapy, Metastatic disease)
- 12 Dec 2025 Registered for Prostate cancer (Combination therapy, Metastatic disease) in USA (PO)